Shaheen Wirk
CIK: 0002050227
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Tvardi releases preclinical data on STAT3 inhibitor for UC. Tvardi Therapeutics reported new preclinical results that show its STAT3 inhibitor may be effective in treating ulcerative colitis. The data were published in the International Journal of Molecular Sciences. The announcement appeared in recent market round‑ups of health‑care stocks moving in pre‑market and after‑hours sessions.
Transaction History
| MOVE | ▲ Buy | Option Exercise | 10,000 | $13K | 3/13/2026 | View on chart |
| MOVE | ▲ Buy | Grant | 2,980 | $0 | 1/9/2026 | View on chart |
| MOVE | ▲ Buy | Grant | 2,980 | $0 | 1/9/2026 | View on chart |
| MOVE | ▼ Sell | Other | 6,841 | $0 | 11/3/2025 | View on chart |
| MOVE | ▲ Buy | Grant | 20,685 | $0 | 10/3/2025 | View on chart |
| MOVE | ▲ Buy | Grant | 18,657 | $0 | 7/3/2025 | View on chart |
| MOVE | ▲ Buy | Grant | 29,070 | $0 | 5/9/2025 | View on chart |
| TVRD | ▲ Buy | Grant | 4,191 | — | 4/15/2025 | View on chart |
| TVRD | ▼ Sell | Other | 176,030 | — | 4/15/2025 | View on chart |
| TVRD | ▼ Sell | Other | 263,164 | — | 4/15/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Corvex files prospectus for share resale and seeks Whitbread board seat
Corvex has filed a prospectus to register the resale of up to 4,258,068 common shares on behalf of selling stockholders. At the same time, an activist linked to Corvex is pursuing a board seat at Whitbread, citing concerns over the company's strategy. The share resale filing could increase the number of shares available in the market, while the activist effort highlights the firm's involvement in governance matters beyond its own operations.
Corvex files prospectus for share resale and seeks Whitbread board seat. Corvex has filed a prospectus to register the resale of up to 4,258,068 common shares on behalf of selling stockholders. At the same time, an activist linked to Corvex is pursuing a board seat at Whitbread, citing concerns over the company's strategy. The share resale filing could increase the number of shares available in the market, while the activist effort highlights the firm's involvement in governance matters beyond its own operations.